PCA
LRMR icon

Pallas Capital Advisors’s Larimar Therapeutics LRMR Stock Holding History

Pallas Capital Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.8K Sell
10,085
-1,077
-10% -$4.28K ﹤0.01% 1002
2026
Q1 		$50.2K Buy
11,162
+994
+10% +$3.97K ﹤0.01% 831
2025
Q4 		$38.7K Sell
10,168
-608
-6% -$2.37K ﹤0.01% 874
2025
Q3 		$34.8K Buy
+10,776
New +$40.4K ﹤0.01% 859

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Pallas Capital Advisors's LRMR Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Larimar Therapeutics (LRMR) stake by 9.6% in Q2 2026, selling an estimated $4.28K and leaving 10,085 shares worth $30.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

Pallas Capital Advisors first reported a position in LRMR in Q3 2025 and has held it in 4 quarters since. The position peaked at $50.2K in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Pallas Capital Advisors held 10,085 shares of Larimar Therapeutics worth $30.8K as of Q2 2026.
  • Pallas Capital Advisors sold 1,077 Larimar Therapeutics shares in Q2 2026, an estimated $4.28K.
  • Larimar Therapeutics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1002 holding.
  • Pallas Capital Advisors first reported a position in Larimar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Pallas Capital Advisors's Larimar Therapeutics position peaked at $50.2K in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.